MannKind to Pitch Growth Story Amid Key Catalysts at Investor Conferences

DANBURY, Conn. – March 04, 2026 – MannKind Corporation (Nasdaq: MNKD) is set to step into the investor spotlight this month, with its leadership team scheduled to present at two prominent healthcare conferences in Miami. The presentations come at a pivotal moment for the biopharmaceutical company, which recently posted robust revenue growth and now faces a series of critical regulatory milestones in 2026 that could reshape its market trajectory.

Chief Executive Officer Michael Castagna and Chief Financial Officer Chris Prentiss will represent MannKind, engaging in fireside chats and one-on-one meetings at the Leerink Partners 2026 Global Healthcare Conference on March 10 and the Barclays 28th Annual Global Healthcare Conference on March 11. For investors, these sessions offer a crucial window into the company's strategy for capitalizing on its recent momentum and navigating the competitive biopharma landscape.

Fortified Financials and Strategic Acquisitions

MannKind's leadership arrives in Miami armed with a compelling financial narrative. The company recently announced strong results for the fourth quarter and full-year 2025, demonstrating significant top-line growth. Total revenues for Q4 2025 surged to $112 million, a 46% increase over the same period in 2024. For the full year, revenues hit $349 million, up 22% from the prior year.

A key driver of this performance is the company’s diversified commercial portfolio. Net sales for Afrezza (inhaled insulin), MannKind's flagship product, grew 25% in the fourth quarter to $23 million. This growth is complemented by the newly acquired FUROSCIX, a subcutaneous treatment for fluid overload in heart failure patients. Following the acquisition of scPharmaceuticals in October 2025, FUROSCIX contributed $23 million in net sales in its first quarter under MannKind's umbrella, a 91% increase over its sales in Q4 2024 under its previous owner.

The strategic acquisition of scPharmaceuticals, valued at up to $360 million, was a defining move in 2025, significantly expanding MannKind’s cardiometabolic franchise. The integration of FUROSCIX and its commercial team is expected to be a central topic of discussion, with investors keen to understand synergy realization and future sales projections. The deal was supported by a non-dilutive financing agreement of up to $500 million from Blackstone, providing the company with substantial capital for growth without diluting shareholder equity.

Further bolstering the revenue picture is the company’s long-standing manufacturing agreement with United Therapeutics for Tyvaso DPI, a treatment for pulmonary hypertension. This partnership generated approximately $100 million in manufacturing revenue in 2025 and provides a stable revenue floor of at least $50 million annually through 2031, lending a degree of predictability to the company's financial model.

A Year of High-Stakes Catalysts

Beyond the balance sheet, 2026 is shaping up to be what CEO Michael Castagna has called a "catalyst-rich year." The company is awaiting FDA decisions on two key product line extensions that could significantly expand its market opportunities.

The first major milestone is the FDA’s review of a supplemental Biologics License Application (sBLA) for Afrezza for pediatric use. With a Prescription Drug User Fee Act (PDUFA) target action date of May 29, 2026, a positive decision would make Afrezza the first and only needle-free, inhaled mealtime insulin available for children and adolescents (ages 4-17) with diabetes. This approval would not only address a significant unmet need for younger patients but also open a substantial new market for the product. The application is supported by positive data from the Phase 3 INHALE-1 study, which demonstrated non-inferiority compared to standard multiple daily injections.

Just two months later, another PDUFA date looms. On July 26, 2026, the FDA is expected to rule on the supplemental New Drug Application (sNDA) for the FUROSCIX ReadyFlow autoinjector. This new delivery system is designed to improve the ease of use for the subcutaneous diuretic, potentially boosting patient and physician adoption. A successful launch of the autoinjector would further validate the strategic rationale behind the scPharmaceuticals acquisition.

Advancing the Pipeline and Navigating Challenges

While near-term catalysts for its commercial products are in focus, MannKind is also advancing its earlier-stage pipeline, centered on its proprietary Technosphere® drug delivery platform. The company is developing Nintedanib DPI (MNKD-201), an inhaled formulation for Idiopathic Pulmonary Fibrosis (IPF). Current oral IPF therapies are effective but plagued by tolerability issues, leading many patients to discontinue treatment. MannKind aims to deliver the drug directly to the lungs, potentially improving tolerability while maintaining efficacy. The first patient was enrolled in a Phase 1b study in December 2025, with a Phase 2 trial expected to begin in the second quarter of 2026. Topline data from the initial study is anticipated in the second half of the year.

However, the path of drug development is not without its setbacks. In late 2025, MannKind announced the discontinuation of its Phase 3 trial for MNKD-101, an inhaled treatment for nontuberculous mycobacterial (NTM) lung disease, following a futility analysis. While disappointing, the decision allows the company to reallocate significant R&D resources toward more promising programs like Nintedanib DPI and the continued expansion of its Technosphere platform.

As MannKind's leadership prepares to meet with investors, they will present a company at a clear inflection point. They will highlight a story of accelerating revenue, successful strategic acquisitions, and a pipeline punctuated by high-impact, near-term regulatory events. The challenge will be to convince the market that its recent financial performance is sustainable and that its upcoming catalysts will translate into long-term shareholder value, solidifying its position as an innovator in chronic disease care. The discussions in Miami will be critical in shaping the narrative for a company navigating both immense opportunity and the inherent risks of the biopharmaceutical industry.